San Diego, (October 13, 2020) – Genalyte, a leading point of care diagnostics and analytics company, announced today the appointment of Ashraf Hanna, M.D. Ph.D, as CEO.
“The selection of Dr. Hanna as CEO reflects Genalyte’s transition to the next phase of the company’s development and growth. The company has established a strong foundation with its FDA-cleared, proprietary Maverick Diagnostic System, as well as its SARS-CoV-2 Multi-Antigen Serology Panel, and is poised to rapidly expand point-of-care testing for the vast majority of tests performed in primary and specialty care settings,” said Jeff Huber, Chairman of Genalyte’s Board of Directors. “Ashraf has proven experience leading transformative healthcare organizations and we are pleased to have him on board.”
“Genalyte is poised to be a major disruptor in the healthcare diagnostic and analytic space, and I am excited to join a company with the ambitious goal of empowering physicians and patients with real-time insights that improve care delivery and reduce costs,” said Dr. Hanna.
Dr. Hanna will take over from Dr. Cary Gunn, Ph.D., who will remain with the organization as founder and Chief Technology Officer, as well as sit on the Board of Directors. Under Dr. Gunn’s leadership, Genalyte has raised over $100M in investments based on the vision of delivering real-time diagnostics and advanced analytics to drive better clinical decisions.
Prior to joining Genalyte, Dr. Hanna served as Chief Operating Officer at Verily Life Sciences. Prior to that role, Hanna served as CEO at ORIC Pharmaceuticals, a biotech company focused on overcoming resistance in cancer. Prior to joining ORIC, Dr. Hanna was Vice President of Commercial and Medical Affairs Finance at Genentech and CFO of the Genentech Foundation. Dr. Hanna holds a Ph.D. in Physics from Harvard University, an M.D. from the University of Massachusetts, and an undergraduate degree in Physics from the University of Chicago.
About Genalyte: Genalyte is a healthcare analytics and diagnostics company that improves patient outcomes and lowers cost with real-time results for physicians and patients. Genalyte delivers rapid, actionable results to doctors through decentralized laboratory testing, backed by remote telehealth oversight and monitoring. For more information, please visit www.genalyte.com.